Skip to main content
Premium Trial:

Request an Annual Quote

Asuragen BCR-ABL Assay Receives CE Mark

NEW YORK (GenomeWeb) – Asuragen today announced its Quantidex BCR-ABL IS CMR Kit has received the CE-IVD mark. 

The firm is launching the kit for monitoring BCR-ABL1 transcript levels in chronic myeloid leukemia patients this week. According to Asuragen, the product improves upon other tests by attaining a sensitivity of MR4.7 while it allows direct reporting on the International Scale. Additionally, the assay enables detection of complete molecular response. 

BCR-ABL1 transcripts arise from a chromosomal translocation called the Philadelphia chromosome that is associated with CML. While tyrosine kinase inhibitors represent a personalized approach to treating CML, and quantitative BRC-ABL1 testing can be crucial in monitoring the effectiveness of TKI therapy, the lack of reporting on the IS has complicated patient monitoring and treatment, Asuragen said. 

Its assay "is a major step forward in providing labs with a BCR-ABL kit with class-leading sensitivity that keeps pace with the advances in TKI therapies and the need for IS standardization," Asuragen President and CEO Matthew McManus said in a statement. 

The Scan

Harvard Team Report One-Time Base Editing Treatment for Motor Neuron Disease in Mice

A base-editing approach restored SMN levels and improved motor function in a mouse model of spinal muscular atrophy, a new Science paper reports.

International Team Examines History of North American Horses

Genetic and other analyses presented in Science find that horses spread to the northern Rockies and Great Plains by the first half of the 17th century.

New Study Examines Genetic Dominance Within UK Biobank

Researchers analyze instances of genetic dominance within UK Biobank data, as they report in Science.

Cell Signaling Pathway Identified as Metastasis Suppressor

A new study in Nature homes in on the STING pathway as a suppressor of metastasis in a mouse model of lung cancer.